• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    (6R,7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino)ace tamido]-3-(1-pyridiniummethyl)ceph-3-em-4-carboxylate in the form of its crystalline pentahydrate. This pentahydrate has a well defined crystalline structure and exhibits good stability on storage. The pentahydrate exhibits excellent antibiotic activity, particularly against organisms which are normally difficult to combat with beta -lactam antibiotics.
    公开号:SU942599A3
    申请号:SU802987392
    申请日:1980-10-01
    公开日:1982-07-07
    发明作者:Купер Броуди Аластайр；Обрей Ветерилл Льюис
    申请人:Глэксо Груп Лимитед (Фирма)；
    IPC主号:
    专利说明:

    salts (6R, 7R) -7- (g) -2- (2-amino-azole-yl) -2- (2-carboxyprop-2. α-hydroxyimino) -acetamido3-3 (1-pyridiniummethyl) cef-3 -) - carboxylate in an aqueous medium adjusted to 2.7, usually 3.0, 0, preferably 3.3, Q, for example, approximately and the target is crystallized , pentahydrate.  The target crystalline hydrate can be precipitated from an aqueous solution of an acid salt by adding an organic or inorganic base to a specified pH value, preferably 3.0, 0.  Bases that can be used for precipitation are inorganic bases, in particular, hydrates of oxides (whole or alkaline earth metals, or their carbonates, or bicarbonates, such as sodium carbonate, sodium bicarbonate or sodium hydroxide.  The starting acid salt can be obtained using an organic or inorganic acid.  Organic acids that can be used for this purpose include carboxylic acids or sulfonic acids, in particular formic, trifluoroacetic acid, toluene-p-sulfonic acid or methanesulfur (an acid.  Inorganic acids that can be used include mineral acids, in particular hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid.  A particularly acceptable acidic salt is the dihydrochloride salt, which can be obtained in pure form.  Pentahydrate can also be obtained by adding acid to a solution of the basic salt in an aqueous medium until the indicated pH value is reached, preferably 3.5 -. 2  Acids that can be used for precipitation are organic or inorganic acids, for example hydrochloric or sulfuric acid.  The starting base salts include alkali metal salts, in particular the sodium or potassium salt, alkaline earth metal salts, in particular the calcium salt, amino acids, in particular the lysine or arginine salt, or organic base salts, in particular ammonium, triethylamine, procaine phenethylbenzylamine, dibenzylethyl diamine, ethanolamine, diethanolamine or methylglucosamine salt.  The aqueous medium may contain water-miscible organic solvents, for example in an amount up to 60 vol. X.  Organic solvents include alcohols, in particular ethanol or isopropanol, ethers, in particular tetrahydrofuran, dioxane or diethyl ether, amides, in particular S, N-dimethylformamide or N, N-dimethyl acetate-amide, sulfoxides, in particular dimethyl sulfoxide, or nitriles, in particular, acetonitrile.  Deposition should be carried out at 0-50 ° C, for example, usually at C, followed by, if necessary, a cooling stage in order to increase the yield of crystals to a temperature in the range.  After precipitation, the pentahydrate can be isolated by filtration, followed by washing and drying.  So, for example, the hydrate can be dried on the breath, by careful drying under reduced donation or in a sterile inert gas atmosphere, in particular sterile nitrogen.  The original product (6R, 7K) 7-G (2) (2-aminothiazol-4-yl) -2- (2-carboxyprop-2-oxyimino) -acetamido-3- (1-pyridiniummethyl) -ceph-3-it -h-carboxylate can be obtained by acylation of a compound of formula YANG  n, i 1.  coo® is preferably in the form of its dihydrochloride acid adduct, an acid of the formula COOH CHs o-c-dooB where R is an amino group or a protected amino group; R is a group protecting the carboxyl group or a corresponding acylating agent, followed, if necessary, by removing the protective group of a doublet; m is a multiplet; ABq - AB Quartet.  Lmberlit L. A. 2 is a weakly basic high molecular weight. secondary amine,. Rom & Haas, Philadelphia, USA. Himflo Super-Sel product is a diatomaceous silica auxiliary filtration powder, supplied by Johns Mineville, USA.  Example A.  (6R, 7R) -7- (Z) -2- (2-Aminothiazol- -yl) -2- (2-carboxyprop-2-oxyimino) acetamido-3- (1-pyridiniummethyl) cef-3 -h-carboxylate dihydrochloride.  84 ml of formic acid are added with stirring to Al, 8 g of (6R, 7R) 7 (2) -2- (2-tritylaminothiazol-yl) -2- (2-tert-butoxycarbonylprop-2-oxyimino) acetamido -3- (1-pyridiniummethyl) -ceph-3 em-4-carboxylate H, N-dimethylformamide solvate, and water cooling is used to maintain the temperature below.  The prepared solution is cooled to 20 ° C and with stirring for 5 minutes it is added with a ml of concentrated hydrochloric acid.  This mixture is stirred for 3 hours at room temperature and then filtered to remove the triphenylmethanol.  The filtrate is added to 800 ml of stirred acetone.  Triphenylmethanol is washed with 3 portions of 7 ml of formic acid and the combined washings are added to the mixture of the filtrate with acetone.  The resulting suspension was stirred for 1.25 hours and then filtered.  The crystalline solid is washed with acetone and dried in vacuo to give 20.2 g of the desired compound.  Found : Ce 11.0 Qi H NbOlSciCeo Calculated: CE 11.5 UV spectrum: A. ji (, Q} cc (rH 6, phosphate buffer) 257 nm (). BUT. InF with (E ,.  310) and bo nm (E: {2I150). P p and m B.  (6R, 7R) -7-TlZ) -2- (2-Aminothiazol-4-yl) -2- {2-carboxyprop-2-oxyimino) -acetamido} -3- (1-pyridiniummethyl) -ceph-3 - eM-t-Kape hydroxulphate hydroxy sulfate, a) 150 ml of 98-100% formic acid are added to 80 g of (6R, 7R) -7-t (Z) -2- (2-triztilaminothiazol-4-yl) - 2- (2-tert-butoxycarbonylprop9 9. . .  8 -2-oxyimino) -acetamido J-3- {1-pyridiniummethyl) -ceph-3-em-4-carboxylate M, M-dimethylformamide solvate and the mixture is stirred until it becomes transparent, and then it is cooled to.  12.6 ml of water and 12.6 ml of concentrated sulfuric acid are added to the solution, after which the temperature is raised to 25 ° C and stirring is continued at this temperature for 5 hours.  The suspension is filtered and the solid residue is washed with several portions of ml of 98-100% formic acid.  The combined filtrate and washings were diluted by adding 200 ml of isopropanol and the resulting solution was added dropwise over 20 minutes into kQQ ml of stirred isopropanol.  LOO ml of isopropyl ether is added to the suspension and stirring is continued for 10 minutes, then filtered.  The solid residue layer was washed with 3 portions of 200 ml of isopropanol and dried for 16 hours in vacuo to give 51.02 g of the title compound in the form of a cream-like solid.  Moisture content: found t, 2; calculated Found: S, 15.2 n, 2n, o Calculated,%: S 14.13 b) The product from step (a) is kept at an elevated temperature in 10 ml of methanol with gentle stirring.  After holding the suspension at room temperature for 2 hours, then holding it for 30 minutes at a solid bed, it is collected by filtration, washed with cold methanol and dried in vacuo for 3 hours, giving 0.9 g of the desired compound.  Found,%: C 38.53; H 3.70; N 12.36; S 14.1; 4.5% 4aa 6 ° i4 2n. 2, о Calculated,% Г С 38.8; H 4.15; N 12.34; S 14.13; NPO 5.3.  UV spectrum ms1 FF. (pH 6.0, phosphate ufer) 257 named (E :; 325), 241 nm (), 289 nm ().  NMR spectrum: T (TFA) 0.90 (d, 3 6 Hz, 2H), 1.32 (t, 3 7 Hz, 1H) and 1.80 (t, L 7 Hz, 2H) (pyridyl H) , 1.40 (d, 3 8 Hz, 1H; NHCO), 2.60 (S, 1H; thiazolyl H), 3.72 and it, 50 (ABq, 3 14 Hz, 2H;) 3, Bk (t , 1H; 7-H), 4.5 (d, D 5 Hz, 1H, 6-H), 6. 06 and 6, Sk (ABq, 3 18 Hz, 2H; 2-H), 8.20 (S, 6H; (sn2,) g).  Below are examples of the preparation of the target (6R, 7R) -7- (1) -2- (2-aminothiazol-C-yl) -2- {2-carboxyprop-2-oxyimino) acetamido-3- (1-pyridinemethyl) -cef-em-i -carboxyl t pentahydrate.  Example 1  2.5b g dihydro-.  The chloride obtained according to Example A is dissolved in 8 ml of distilled water and stirred for 2-3 minutes until the solution is clear, then 1, O ml of 98% formic acid is added to it.  The mixture is mixed together with Amberlite L. liquid anir-exchange resin. A. 2 (ml) in 8 ml of diisopropyl ether, then allowed to stand and separated.  The aqueous layer is subjected to extraction treatment in 2 portions of 5 ml of diisopropyl ether, and the resin layer is washed with 5 ml of distilled water, which, in turn, is extracted by extraction with two m | zopropyl ester extracts.  The combined aqueous layers (pH), which contain an ant salt of a different acid, are mixed during the addition of 8-10 drops of ammonia solution to them in order to adjust the pH.  to 3.7, after which the clear solution is allowed to stand for gradual crystallization at room temperature for 1 hour and then at room temperature overnight.  The target compound is collected by filtration, washed with 2 portions of b5 ml of chilled distilled water and 2 portions of 10 ml of acetone and dried, at room temperature in an oven with an air flow for 2 to obtain 2.0 g of crystalline solid.  UV spectrum: (L0s (rF 6 buffer), 257 nm ().  NMR spectrum: OT (h-TPA) 0.98; 1.3b; 1.8 (pyridine protons); 2.80 (thiazole); , 05 (); 4.15 and 4.58 (-CH,) ;. 4.64 (C. -H); 6.21 and 6.67 () and 8.40 {- ().  IR spectrum: max (nudzhol) 17bO (beta-lactam); 1710 (SOAH); 1645 and 1538 (CONH) and 1620 cm (COG).  10 Moisture content: found 13.6; calculated I ,.  Residual chlorine 0, U.   5NgO Example 2.  2, Or the dihydrochloride prepared according to Example A is dissolved in 12 ml of distilled water and stirred while the ammonia solution is added to the solution until the pH is reached. The clear solution is then allowed to crystallize at room temperature for 0.5 hours, The pH is adjusted to 3.8 with an ammonia solution and the suspension is maintained at for 1 h.  The target compound is collected by filtration, washed with 10 ml of cold water and acetone, and then dried under vacuum at room temperature for 3 hours, giving 1.5 g of crystalline solid.  UV spectrum: CMS (cc (pH 6, buffer) 257 nm (El, ° 356), (TPA).  The NMR spectrum is similar to that shown in example 1.  Moisture content,%: found 13.8; calculated 14.1.  Residual chlorine 0.1 o.  Found: C 41.5; H - 4.73; N 13.17 4a42 “i fe07 O.  5H (iO Calculated,%: C 41.5; H 5.05; N 13.2.  Example 3-2.0g of dihydrochloride, prepared as described in Example A, is dissolved in 6 ml of distilled water and the solution is stirred during the gradual addition of 2N.  sodium hydroxide solution until the pH reaches 3.8.  Then crystallization is carried out, during which the pH value rises to 4.5, after which it is again lowered to 3.8 by adding a few drops of 2N.  hydrochloric acid.  The suspension is cooled in an ice bath, and the target compound is collected by filtration, washed with 10 ml of a mixture of water with ice and acetone, and then dried at room temperature in air for 2 hours, resulting in 1. 5b g of crystalline solid.  UV spectrum: Hmax (pH 6, buffer).  257 nm (E 354), (+ TPA).  The NMR spectrum is similar to that specified in example 1.  Moisture content k, k%, residual chlorine 0.1%.  Example k, k, Qg of dihydrochloride, prepared analogously to measure A, is dissolved in N ml of distilled water and the solution is stirred while 13 ml of a saturated aqueous solution of sodium bicarbonate is added to bring the pH to 3.8.  The product crystallizes rapidly.  The suspension is cooled in an ice bath, collected by filtration, washed with 20 ml of a mixture of water with ice and acetone, and then dried at room temperature in a furnace for 2 hours of air drying, resulting in 3.1 g of crystalline solid. product.  UV spectrum: ((buffer with pH 6) 257 nm rE: {gS 358U nm) 290 nm (nLo 157).   The moisture content of 13.9% of the IR spectrum is similar to that specified in example 1.  Example 5- South of the hydrogensulfate obtained according to Example B (a) is dissolved in 20 ml of water and cooled until stirred.  An ammonia solution with a specific gravity of 0.88 is added to the stirred solution in the quantity necessary to bring the pH to 3.75, with a rise in temperature to 25 ° C.  A seed amount of the target compound is added to the mixture, after which it is kept at a reduced temperature of 16 hours.  The pH of the final suspension is again adjusted to 3.75 by the addition of a small amount of ammonia solution, and then filtered.  The filter residue is washed with 2 portions and 15 ml of cold water and 50 MP of acetone each.  The resulting product is dried for 6 hours at room temperature in a dryer, whereby 3.8 g of the desired pentahydrate are obtained.  Moisture content T, 2%.  The NMR spectrum is similar to that specified in example 1.  Example 6  9, g of crystalline hydrosulfate, prepared according to Example B (b), are dissolved in 19 ml of water with a solution of a few drops of ammonia solution with a specific gravity of 0.88 added.  Then re-.  the mixed solution is cooled to 15 ° C and an additional amount of ammonia solution is added to it with the pH adjusted to 3.75 with stirring and the temperature is 25 ° C.  A seed amount of the desired compound, and cooling is then added to this mixture.  give it to, after which it is kept at this temperature for 16 hours  The pH value of the suspension is next to AGNOVODovod t to 3.75, adding to it a few drops of 2 n.  Sulfuric K1 slots, and then filtered.  The filter cake is washed with 2 portions of 15 ml of cold water and 50 ml of acetone.  The product is dried for 6 hours at room temperature in a dryer, whereby 5.6 g of the title compound are obtained.  Moisture content k, Q%.  The NMR spectrum is similar to that specified in example 1.  Example7.  The south of the dihydrochloride obtained according to Example A is dissolved in 40 ml of distilled water and the solution is stirred while adding 20 ml of 2N to it.  sodium hydroxide solution to bring the pH to 6.  The sodium salt solution thus prepared is kept at room temperature for 3 hours and then clarified by filtration.  The filtrate is stirred with the addition (1 in it 7 ml 2 n.  hydrochloric acid with pH adjustment.  The suspension is maintained at a lowered temperature for 2 hours, and the precipitate is collected by filtration, washed with 50 ml of a mixture of ice-water and 50 ml of acetone, and then dried at room temperature in a dryer for 2 hours, resulting in a yield of 8.01 g of crystalline target. product.  The NMR spectrum With (DQip + TFA), similar to that specified in example 1.  Example 8  20 g of the dihydrochloride obtained according to Example A is dissolved in 50 ml of distilled water and about 10 ml of 2N CO are added to the stirred solution.  sodium hydroxide solution. adjusting the pH to 6, resulting in a solution of the sodium salt.  Then, 20 mg of sodium dithionite is added and the solution is cooled to.  5N is added to the stirred solution.  a solution of sulfuric acid to bring the pH to 3.8.  The suspension is kept at rest at room temperature for 1.5 hours, cooled to, and the desired compound precipitated is collected by filtration, washed with 60 ml of a mixture of water with ice and 60 ml of acetone, and then dried in a dryer at room temperature. resulting in 1b, 6 g of a crystalline target compound.  NMR spectrum, C (TFA), similar to that specified in example 1; Ylagi content, 2%.  Example 9  The pH of the solution of rastvore 10 g of dihydrochloride ingested according to example A in 20 ml of ice-cold distilled water is adjusted to 6 by adding approximately 24 ml of 2N to it.  sodium hydroxide solution.  The potassium salt solution thus prepared is clarified by filtration using 1 g of the product Chimflo Super-Sel and washed with 10 ml of water.  The filtrate is acidified to pH 3.5 by adding about 7 ml of 2N.  sulfuric acid solution and enter into it 0.05 g of the target compound as a seed. The crystallization operation is carried out without stirring for 1 hour.  The pH is then adjusted to 3.5 and the suspension is cooled to.  The target compound is collected by filtration, washed with ice-cold water (CO ml) and then tO ml of acetone, and then dried in a dryer at room temperature, resulting in 7.8t g of product.  Moisture content} C, 2%; The NMR spectrum, b (TFA), is similar to that shown in Example 1.  An example.  A solution of 10 g of di-hydrochloride, prepared according to Example-A, in 20 ml of ice-cold water is treated by addition. 2 n.  ammonium hydroxide solution (approximately 2 ml), bringing its pH to 7.2.  The ammonium salt solution prepared in this way was clarified by filtration, and then the filter was treated by adding 2N sulfuric acid thereto as in Example 9, resulting in a yield of 5.93 g of the target compound. Moisture content 1.2; NMR spectrum C ( TPA), similar to that shown in example 1. .    Example 11  The pH of the solution of 10 g of the dihydrochloride obtained according to Example A in ml of ice-cold water is adjusted to 6.5 by adding dropwise 6.55 ml of triethylamine.  The solution of the triethylamine salt prepared in 9I is clarified as in Example 9 and the filtrate is acidified to bring the pH to 3.5 by adding approximately 8 ml of 2N to it.  hydrochloric acid, and the product is isolated, resulting in 7.13 g of the title compound.  The moisture content k,%, NMR spectrum, 1 (TPA), is similar to that shown in example 1.  Example 12  The pH of the dihydrochloride solution prepared according to Example A (10 g) in 20 ml of ice-cold water is adjusted to 6 by adding dropwise to it approximately ml of 2N.  sodium hydroxide solution.  The sodium salt solution thus prepared was clarified by filtration using 1 g of the product Chimflo SuiperSel and washed with 10 ml of water.  The solution is then cooled to -2 ° C, acidified to pH 3.5 by the addition of about 8 ml of 2N.  sulfuric acid solution and the target compound is injected into it.  Next, the solution is stirred at 3 h.  The target compound is collected by filtration, washed with tO ml of cooled 41 h of water and dried at room temperature in a dryer, resulting in 7.7 g of product with a moisture content of 1.2.  Values 1 (TPA) analogues-nb.  specified in example 1.  Example 13  The pH of the solution is 10 g of dihydrochloride, semi-.  According to Example A, in 20 ml of distilled water, make up to. 6 by adding about 2 ml of 2N to it.  sodium hydroxide solution.  The sodium salt solution thus prepared is clarified by filtration. Add 1 g of Himflo Super-Sel product and wash with 10 L of water.  The solution is then heated to and acidified by adding about 8 ml of 2N to it.  sulfuric acid, bringing its pH to 3.5, after which 50 mg of the target compound is added as a seed material.  The crystallization of the WTF is followed by stirring for 1 h and the pH is adjusted to 3.5. The suspension is filtered and the precipitate is washed with 0 ml of ice-cold water, then "O ml of acetone, and then dried in a dryer at room temperature 2.11 g of the title compound with a moisture content of l.  Values with (TFA) are similar to those specified in example 1.  Example N.  After soaking for 1 hour with the suspension prepared according to Example 13, it is allowed to cool for 1 hour before, after which it is cooled to 5 ° C for another 1 hour.  The target compound is collected by filtration, washed with 40 ml of ice-cold water and then with O ml of acetone and dried in dry condition at room temperature to obtain 6.9 g of product with a moisture content of 1t, 3.  The values of T (TFA) are similar to those specified in example 1.  Example 151 2.0 kg of the dihydrochloride prepared according to Example A is dissolved in 5 liters of freshly prepared distilled water and the solution is acidified, bringing its pH to 6 by adding about 8 liters of 2N to it.  sodium hydroxide solution, maintaining the solution temperature at level C.  The sodium salt solution prepared in this way is sterilized by passing through a membrane filter (with a pore size of 0.22 µm), which then passes 0.5 l of freshly prepared distilled water. Subsequently, all operations are carried out under aseptic conditions.  The pH of the filtered solution was adjusted to 3.75 by adding 2 p 2 n to it.  hydrochloric acid and, as a seed material, 20 ml of the sterilized target compound are introduced into this solution with and then stirred until the crystallization is complete.  The mixture is then cooled to and kept at this temperature without stirring overnight.  The pH value is again adjusted to the required level, t. e.  3.75.  The target compound is collected by filtration using a fiber-free nylon net and washing with ice-cold water for injection (approximately 5.5 L) and sterilized with acetone (approximately 1 L).  The product is dried in a stream of sterile filtered nitrogen to bring acetone to a level below 0.2, resulting in a yield of 1.48 kg of a sterile target compound with a moisture content of 1.55%.  Values 916 ((TPA) are similar to those specified in example 1. .  Example 16  5 g of the dihydrochloride prepared according to Example A is dissolved in mixtures of distilled water with acetone (each up to 20 ml), which contain different amounts of acetone in the range of 5-60, as well. then the solution is cooled to.  The pH of the solution was adjusted to 3.5 by adding 2 n.  sodium hydroxide solution and immediately thereafter, 0.015 g of the target compound is added to the solutions as a seed material.  The mixture is then kept at 21-23 ° C for 90 minutes without stirring, and then cooled to 12 ° C with stirring, after which their pH is adjusted to 3.5. After holding for an additional 1 hour. At S, the solid product is isolated by filtration, washed 25 ml of water at 5 ° C and 25 ml of acetone.  The product is then dried in a dryer at room temperature to constant weight, with the result that the desired compound is obtained.  After completing the above procedure, the target compound is obtained from dihydrochloride by crystallization from water, which contains ethanol, isopropanol, tetrahydrofuran, dioxane, diethyl ether and ethyl acetate.  Example 17  In addition, samples of dihydrochloride prepared according to Example A are dissolved in 20 milliliter portions of distilled water, and the resulting solutions are rapidly cooled with vigorous stirring until.  Then the pH values of the solutions are adjusted by adding 2 n dropwise to them.  sodium hydroxide solution.  After the addition of 0.015 g of the identified target compound as a seed material, the mixtures are incubated for 90 minutes at room temperature without stirring.  They are then cooled down with stirring and pH adjustment, after which the mixture is kept without stirring for an additional 1 hour at. .  The target compound is isolated by vacuum filtration and in each case washed with 25 ml of distilled water at 5 ° C and then 25 ml of acetone, followed by drying to constant weight in a dryer at room temperature.
    In tab. 2 shows the yield values of the target compound at various pH values in combination with the moisture content data.
    The results of the NMR spectrum are similar to those shown in example 1.
    table 2
    In tab. 3 shows the yield of the target compound obtained at different pH values, together with the moisture content of the product.
    NMR data is identical to that shown in Example 1.
    Table 3
    Example 18. The B-gram samples of the dihydrochloride prepared according to Example A were dissolved in 10-ml portions of distilled water and the resulting solution was cooled rapidly to vigorous stirring. After adjusting the pH to 6 by adding dropwise 2 n. Sodium hydroxide solution solution The resulting sodium salt solutions are incubated without stirring for 10 minutes. Further, these solutions are acidified with the achievement of the specified pH values by adding in drops of cubic meters and. sulfuric acid and immediately thereafter, 0.015 g of the identified target compound is added as seed material. After keeping at room temperature for 0 minutes, without stirring, the mixture is cooled to 5 ° C with stirring and pH adjustment, and the drain is kept for 2 hours at 5 ° C without stirring. The target compound is isolated by vacuum filtration and in each case washed with 25 ml of distilled water at, and then with 25 ml of acetone at Cj, and then dried to constant weight in a dryer at room temperature. The crystalline pentahydrate of the formula (O exhibits antibiotic properties and can be used to treat various diseases caused by pathogenic bacteria in both humans and animals, particularly in the respiratory tract infection, as well as in the urinary tract infection. Pharmaceutical compositions based on The pentahydrate can be prepared using any necessary pharmaceutical fillers, carriers or bases for the preparation of drugs. The pentahydrate can be used to prepare the preparation intended for injection as well as in single doses in the form of ampoules or multi-dose vessels in combination, if necessary, with preservative additives. Compositions can also be prepared in such forms as suspensions, solutions or emulsions in oil-like or aqueous carriers, and they may contain conventional additives added to preparations, in particular suspending agents, stabilizing and / or dispersing agents. To combine with a suitable basis for the preparation of a drug, for example, sterile water that does not contain pyrogen, before using the active component, it is desirable that it can be converted into powder form. Preferably, powdered preparations should also contain a corresponding non-toxic base, which allows for improving the water solubility of the active component and / or ensuring that such a powder is combined with water to achieve such a pH of the resulting aqueous composition that is physiologically acceptable. Alternatively, this base can be introduced into water, with which subsequent powder combination is envisaged. As such a base, for example, an inorganic base can be used, in particular sodium carbonate, sodium bicarbonate, tertiary sodium orthophosphate or sodium sulfate, or an organic base, in particular lysine, lysine acetate, tromethamine, arginine or sodium glycinate. Suppositories can also be made using pentahydrate, for example, including conventional suppository bases, in particular cocoa butter and other glycerides. For treatment of the eyes and ears, devices can be made as individual capsules in liquid or semi-liquid form, as well as in the form of drops. Compositions for veterinary purposes can be prepared in the form of preparations for introduction into the mammary gland or of a long-acting type, or as rapidly excreting bases. These compositions may contain from 0.1% and above, for example, from 0.1 to 99, the active material, depending on the method of introduction into the body. When such compositions are unit dosages, each dosage preferably should contain 501,500 mg of active ingredient. The dosage used for the treatment of adults should be 500 BOOO mg / day, depending on the route and frequency of administration. For example, in the treatment of adults, a daily dosage of 1000-3000 mg for intravenous or intramuscular administration is satisfactory. In the treatment of microorganisms Pseu9 920 domonas, larger daily dosages may be used. The pentahydrate of formula (I) can be introduced into the body in combination with other therapeutic agents, in particular in combination with antibiotics, for example penicillins or other cephalosporins. The pharmaceutical compositions can be illustrated using the following preparations. Preparation A, for injection, mg: (6R, 7R) -7-r (Z) -2- (2-aminothiazol-4-yl) -2- (2-carboxyprop-2-oxyimino) -acetamido-3- ( 1-Pyridinium methyl-ceph 3-em-4-carboxylate pentahydrate 582 Sodium carbonate (anhydrous) 58 Cephalosporin hydrate is mixed with sodium carbonate and transferred to a glass vial. The head space of the vial is purged with nitrogen and the combined seal is performed by crimping. This product is dissolved in the body by adding 2 ml of water for injection. Drug B, double package for injection. a) Sterilized (6R, 7R) -7- (L) -2- (2-aminothiazol-4-yl -2 - (2-carboxyprop-2-oxyimino-acetamido3-3- (1-pyridiniummethyl) cecene 3-e-t-carboxylate pentahydrate is transferred to glass vials with a protective layer of sterilized azod in such a way that each vial contains the amount of material equivalent to 500 mg of anhydrous cephalosporin. Then the vials are closed with rubber discs or stoppers that are secured with aluminum seals which prevents gas exchange with the environment or the penetration of microorganisms. b) D remove the solution with a concentration of 3.8 w / v of bicarbonate, lighten it by filtration and put 2.15 ml of this solution in clean ampoules. Before sealing, the carbon dioxide is blown through the contents of each ampoule. Next, the ampoules are sterilized in an autoclave and checks their contents for transparency.
    权利要求:
    Claims (1)
    [1]
    Claim
    582
    167 with L-argis) Cephalosporin antibiotic should be prepared shortly before its · introduction into the body by dissolving in 2.0 ml of sodium bicarbonate solution.
    Drug C, for injection, mg:
    (6R, 7R) -7 “[(Z) -2- (2-aminothiazol-4-yl) -2- (2-carboxyprop-2-hydroxyimino) acetamido]“ 3 ”(1-pyridiniummethyl ') -ceph -3 ~ em-4-carboxylate pentahydrate L-arginine Cephalosporin is mixed with Nin and the mixture is placed in a glass bottle. The bottle neck is purged with nitrogen and the combined seal is fired. To introduce this drug into the body, the product is dissolved by adding 1.5 ml of water for injection to go.
    Preparation 0, for injection, (6R, 7R) -7 - [(Z) -2- (2-aminothiazol-4-yl) -2- (2-carboxyprop-2-hydroxyimino) - acetamido) -3 “(1 -pyridiniummethyl) -ceph-3 ~ em-4 carboxylate pentahydrate L-arginine Primary acid phosphate dihydrate Sterile primary acid phosphate L-arginine is stirred under aseptic conditions. Further, the resulting powdery mixture is also mixed under aseptic conditions with sterilized cephalosporin. Under aseptic conditions, glass vials are filled with this mixture under a protective layer of sterilized nitrogen gas. Then these bottles are closed with rubber discs or plugs, which are closed with aluminum sealing housings, which helps to prevent gas exchange with the environment and the penetration of microorganisms -
    类似技术:
    公开号 | 公开日 | 专利标题
    SU942599A3|1982-07-07|Process for producing |-/|-2-|-2-|-acetamido/-3|-ceph-3-em-carboxylate pentahydrate
    PT1556389E|2007-11-08|Cephem compounds
    US4241057A|1980-12-23|Antibiotic compositions
    PL172835B1|1997-12-31|7-beta-[|-2-|-2-hydroxyiminoacetamide]-3-|-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, crystalline hydrate of 7-beta-[|-2-|-2-hydroxyiminoacetamide]-3-|-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, method of obtaining these compounds, pharmaceutical preparation and method of fighting against bacteriae
    SU753361A3|1980-07-30|Method of preparing 7-acylamino-3-cephem-4-carboxylic acid unsaturated derivatives or their salts
    US4467086A|1984-08-21|Cephalosporin antibiotic
    CA1338780C|1996-12-10|Water-soluble antibiotic composition and water-soluble salts of new cephem compounds
    US4128715A|1978-12-05|Cephalosporin antibiotics
    SU845789A3|1981-07-07|Method of preparing d-7-/alpha-|-alpha-|-acetamido/-3-| thiomethyl-3-cephem-4-carboxylic acid
    KR840002163B1|1984-11-24|Process for preparing 7-beta-|-acetamido)-3-|-methyl)-3-cephem-4-carboxylic acid and c1-c6 alkyl derivatives
    US5134137A|1992-07-28|Cephalosporin antibiotics
    US5223496A|1993-06-29|Cephalosporin antibiotics
    RU2029549C1|1995-02-27|Antibiotic composition
    AU612414B2|1991-07-11|Cephalosporin derivatives with improved pharmacokinetics, process for their preparation, pharmaceutical compositions in which they are present and synthesis intermediate
    US4296112A|1981-10-20|Cephalosporins
    US4283398A|1981-08-11|Cephalosporins
    FI60019B|1981-07-31|FOERFARANDE FOER FRAMSTAELLNING AV ANTIBAKTERIELLA 7 - | -ACETAMIDO) -3-HETEROCYCLISK-THIOMETHYL-3-CE-METHYL-3-CEF
    DK157686B|1990-02-05|METHOD OF ANALOGUE FOR THE PREPARATION OF 7-BETA SUBSTITUTED IMIDAZOLIDINYL-3-CHLOR-3-CEPHEM-4-CARBOXYLIC ACID OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
    DE2906843A1|1979-09-13|7- ANGLE CLAMP ON ANGLE CLAMP ON AMINO | ACETYL SQUARE CLAMP ON AMINO SQUARE CLAMP ON CEPHALOSPORINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
    EP0128028A2|1984-12-12|Cephalosporin derivatives, their production and use
    CS199295B2|1980-07-31|Process for preparing new 7-n-acylamino-alpha-aryl or thienylacetamido-3-/heterocyclothiomethyl/-3-cephem-4-carboxylic acids
    CS199293B2|1980-07-31|Method of producing 7-/n-acylamino-alpha-aryl or thienyl-acetamido/-3-/heterocyclothiomethyl/-3-cephem-4-carboxylic acids
    GB2045238A|1980-10-29|Novel cephalosporins
    MXPA98006508A|1999-09-01|New compounds of cefem and pharmaceutical use of mis
    同族专利:
    公开号 | 公开日
    PL227019A1|1981-06-05|
    AT368161B|1982-09-27|
    NL8005443A|1981-04-06|
    DK414780A|1981-04-03|
    NO802913L|1981-04-03|
    YU249780A|1983-02-28|
    NO156246C|1987-08-19|
    HU184835B|1984-10-29|
    FI803126L|1981-04-03|
    CS214721B2|1982-05-28|
    NO156246B|1987-05-11|
    CA1142919A|1983-03-15|
    KE3641A|1986-07-11|
    AU539519B2|1984-10-04|
    JPS5657791A|1981-05-20|
    GB2063871A|1981-06-10|
    KR840001776B1|1984-10-19|
    CY1338A|1987-01-16|
    DD153376A5|1982-01-06|
    PT71860B|1982-04-02|
    FR2466467A1|1981-04-10|
    BE885489A|1981-04-01|
    ES495534A0|1981-09-01|
    HK78686A|1986-10-24|
    DK155525C|1989-09-04|
    RO82721B|1984-10-30|
    DK155525B|1989-04-17|
    IT1144006B|1986-10-29|
    FI71157B|1986-08-14|
    AU6288280A|1981-04-09|
    ECSP941099A|1995-01-16|
    ATA490080A|1982-01-15|
    DE3037102C2|1986-04-10|
    GB2063871B|1983-06-02|
    KR830004317A|1983-07-09|
    FI71157C|1986-11-24|
    SE449614B|1987-05-11|
    FR2466467B1|1984-02-10|
    UA7208A1|1995-06-30|
    YU42357B|1988-08-31|
    PT71860A|1980-11-01|
    JPH0128036B2|1989-05-31|
    PL126606B1|1983-08-31|
    GR69123B|1982-05-03|
    SE8006861L|1981-04-03|
    CH645118A5|1984-09-14|
    US4329453A|1982-05-11|
    MX6545E|1985-07-10|
    RO82721A|1984-09-29|
    NL190329B|1993-08-16|
    DE3037102A1|1981-04-23|
    NL190329C|1994-01-17|
    ES8106908A1|1981-09-01|
    MY8500315A|1985-12-31|
    BG33586A3|1983-03-15|
    IT8049783D0|1980-10-01|
    ZA806081B|1982-05-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    AR228726A1|1978-05-26|1983-04-15|Glaxo Group Ltd|PROCEDURE FOR THE PREPARATION OF ANTIBIOTIC -7 - -2- -2- ACETAMIDO) -3- CEF-3-EM-4-CARBOXILATO|US4443444A|1980-08-11|1984-04-17|Fujisawa Pharmaceutical Co., Ltd.|Cephem compounds|
    US4427677A|1980-12-31|1984-01-24|Fujisawa Pharmaceutical Co., Ltd.|Cephem compounds|
    US4394503A|1981-12-07|1983-07-19|Bristol-Myers Company|Cephalosporin derivatives|
    US4474954A|1981-12-07|1984-10-02|Bristol-Myers Company|Intermediates for cephalosporin derivatives|
    JPH0144189B2|1982-05-14|1989-09-26|Meiji Seika Co|
    ES525492A0|1982-09-10|1985-02-01|Glaxo Group Ltd|A PROCEDURE FOR THE PRODUCTION OF A HERMETICALLY CLOSED CONTAINER CONTAINING AT LEAST ONE BETA-LACTAMA ANTIBIOTIC.|
    DE3313818A1|1983-04-16|1984-10-18|Hoechst Ag, 6230 Frankfurt|NEW CEFTAZIDIM CRYSTAL MODIFICATION|
    DE3313816A1|1983-04-16|1984-10-18|Hoechst Ag, 6230 Frankfurt|NEW CEFTAZIDIM CRYSTAL MODIFICATION|
    GB8406218D0|1984-03-09|1984-04-11|Glaxo Group Ltd|Process|
    US4537959A|1984-03-26|1985-08-27|Eli Lilly And Company|Crystalline cephalosporin antibiotic salt|
    JPS60231683A|1984-05-02|1985-11-18|Teijin Ltd|Cephalosporin derivative, its preparation, and antimicrobial agent comprising it as active ingredient|
    US4616080A|1984-07-02|1986-10-07|Eli Lilly And Company|Simplified process of forming crystalline ceftazidime pentahydrate|
    US4626534A|1984-07-23|1986-12-02|Eli Lilly And Company|Pharmaceutical formulation|
    DE3577656D1|1984-07-23|1990-06-21|Lilly Co Eli|PHARMACEUTICAL COMPOSITIONS OF CEFTAZIDIM.|
    US4659813A|1984-11-08|1987-04-21|Eli Lilly And Company|Crystallization process for ceftazidime derivative|
    DE3581619D1|1984-11-08|1991-03-07|Lilly Co Eli|METHOD FOR PRODUCING CRYSTALLINE CEFTAZIDIME PENTAHYDRATE.|
    US4994451A|1988-01-19|1991-02-19|Bristol-Myers Company|Cephalosporin salts and injectable compositions|
    US5244891A|1985-08-05|1993-09-14|Bristol-Myers Squibb Company|Injectable compositions of cefepime dihydrochloride hydrate|
    US4910301A|1985-08-05|1990-03-20|Bristol-Myers Company|Cefepime cephalosporin salts|
    US4954624A|1986-10-07|1990-09-04|Sandoz Ltd.|Process for the production of cephalosporin derivatives|
    AT387390B|1986-10-07|1989-01-10|Biochemie Gmbh|METHOD FOR PRODUCING THE ANTIBIOTIC-7--2- (2-CARBOXY|
    EP0278656B1|1987-02-02|1992-06-03|Eli Lilly And Company|Process for preparing ceftazidime pentahydrate|
    US5021564A|1987-02-02|1991-06-04|Eli Lilly And Company|Process for preparing ceftazidime pentahydrate|
    KR950010084B1|1987-06-25|1995-09-06|반유세이야꾸 가부시끼가이샤|The preparing process for crystallic cephal sporin compounds|
    WO1988010262A1|1987-06-25|1988-12-29|Banyu Pharmaceutical Co., Ltd.|Crystalline cephalosporin compound|
    GB8802622D0|1988-02-05|1988-03-02|Glaxo Group Ltd|Chemical compound|
    KR940000112B1|1990-07-05|1994-01-05|주식회사 대웅제약|3-substituted cephem compounds|
    US5831085A|1997-01-16|1998-11-03|Lupin Laboratories Limited|Process for manufacture of cephalosporin such as ceftazidime and intermediate thereof|
    CN1328281C|2004-11-16|2007-07-25|广州白云山制药股份有限公司|Ceftazidime pentahydrate purifying method|
    CN102924483B|2012-10-31|2015-06-17|海南合瑞制药股份有限公司|Ceftazidime crystal compound, preparation method of compound and pharmaceutical composition of compound in sterile mixed powder form|
    CN102875576A|2012-10-31|2013-01-16|苏州致君万庆药业有限公司|Synthesis of antibiotic ceftazidime, ceftazidime for injection and preparation method of ceftazidime|
    CN104876949A|2015-05-28|2015-09-02|浙江长典医药有限公司|Ceftazidime compound entity and preparation thereof for children|
    CN106420658A|2016-09-23|2017-02-22|临沂草之美医药科技有限公司|Ceftazidime capsule for treating surgical infection|
    CN109111467A|2017-06-22|2019-01-01|宁应|One kind 51/4His acridine compound of head spore and its drug combination preparation|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB7934204|1979-10-02|
    [返回顶部]